Autonomix Medical, INC S-1 registration statements

Autonomix Medical, a development-stage medical device company, filed an S-1 registration statement for the resale of up to 2.5 million shares, including a $15 million committed equity financing facility with Lincoln Park Capital, as it progresses its neuromodulation technology for pain management and other disorders.

Autonomix Medical, Inc. details the terms and conditions for its Series B Common Stock Purchase Warrants, including exercise price, limitations, and adjustment provisions.

Autonomix Medical, a development-stage medical device company, filed an S-1 registration statement for the resale of common stock underlying warrants, highlighting positive clinical trial results for its pain management system while facing significant going concern doubts.

Autonomix Medical is launching a firm commitment public offering to raise up to $9 million for clinical trials and development of its nerve-sensing and treatment technology.

Autonomix Medical launches a unit offering to raise capital for clinical trials and development of its innovative nervous system disorder treatment platform.